HIV New Product Introduction Toolkit

CHAI is pleased to release the fifteenth issue of our annual HIV market report. The 2024 HIV Market Report provides a detailed look at...

Introducing the eighth edition of CHAI’s HIV Mid-Year Market Memo, a brief that covers the latest trends in the HIV space in low- and...

This slide deck, presented by CHAI at IPHASA 2023, outlines planning considerations for the introduction of pALD throughout all stages of...

CHAI is pleased to release the fourteenth issue of our annual HIV market report. This report provides a detailed look at the complex,...

This treatment optimization roadmap is a resource for Ministries of Health and partner organizations. It offers a summary of pediatric...

This document is meant to answer some of the most common questions that surround pediatric darunavir/ritonavir 120/20mg (pDRV/r) - a new...

This product profile provides a clinical overview of the best-in-class protease inhibitor (PI) formulated in a fixed-dose combination...

Introducing the seventh edition of CHAI’s HIV Mid-Year Market Memo, a brief that covers the latest trends in the HIV space in low- and...

This document is meant to answer some of the most common questions surround the fixed-dose combination of pediatric...

This product profile provides a clinical overview of the fixed-dose combination of pediatric abacavir/lamivudine/ dolutegravir 60/30/5 mg...

The GAP-f pDTG task team has developed a brief outlining product introduction and rollout considerations for national programmes when...

The Transitioning children to Optimal Regimens of Paediatric Dolutegravir (TORPEDO) Study was conducted in Benin, Nigeria, and Uganda....

CHAI is pleased to release the 13th issue of our annual HIV market report. This report provides a detailed look at the complex,...

Introducing the sixth edition of CHAI’s HIV Mid-Year Market Memo, a brief that covers the latest trends in the HIV space in low- and...

In mid-2021, national HIV programmes began to transition treatment for children living with HIV to dolutegravir (DTG) 10 ...

CHAI developed these frequently asked questions (FAQs) to lay out information for communities and PLHIV on the subject of DRV/r (400/50...

Darunavir (DRV) is a best-in-class protease inhibitor (PI) used in combination with other antiretroviral (ARV) drugs for the...

A presentation with the latest information on DRV/r (400/50mg) and considerations for adult second line treatment optimization.

CHAI developed these frequently asked questions (FAQs) to lay out information for national HIV programs considering the adoption and...

Regional HIV Market Briefs, produced by the CHAI HIV Access Program, provide the latest region-specific market intelligence on ART...